According to the latest report by IMARC Group “Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The global human insulin market reached a value of US$ 40.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 63.5 Billion by 2027, exhibiting a CAGR of 8.6% during 2022-2027.
Human insulin (HI) is short-acting insulin produced in laboratories. It is commonly used to replicate the function of human insulin and is bio-engineered by cultivating insulin proteins within E-coli bacteria (Escherichia coli). It comes as a solution and a suspension and must be injected subcutaneously. It is frequently used to manage blood sugar levels in people with type I and type II diabetes.
HI works by assisting the movement of sugar produced by the human body from the blood to other body tissues where it is consumed for energy. It can also prevent the liver from creating more sugar. Aside from that, HI aids in reducing hepatic glucose production and increasing the body’s protein synthesis.
Market Trends:
One of the primary factors driving the market is the rising prevalence of obesity and diabetes among individuals as a result of sedentary lifestyles. Aside from that, there is a huge increase in demand for biosimilar medications due to their cost-effectiveness and higher efficiency, which is boosting market expansion. In addition, important competitors are introducing pen devices and safety pen needles to increase insulin administration to the body. This, combined with increased research and development (R&D) activities, is another growth-inducing component.
Request for a free sample copy of this report: https://www.imarcgroup.com/human-insulin-market/requestsample
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- B. Braun Melsungen AG
- Becton Dickinson & Company
- Biocon
- Eli Lilly and Company
- Julphar
- Novo Nordisk
- Pfizer
- Sanofi
- Sedico
- Wockhardt
- Ypsomed Holding, etc.
Explore full report with table of contents: https://www.imarcgroup.com/human-insulin-market
The report has segmented the market on the basis of Product Type, End-User and Region.
Breakup by Product Type:
- Drugs
- Human Insulin Analogs and Biosimilars
- Rapid Acting
- Long Acting
- Premixed
- Human Insulin Biologics
- Short Acting
- Intermediate Acting
- Premixed
- Human Insulin Analogs and Biosimilars
- Delivery Devices
- Pens
- Reusable Pens
- Disposable Pens
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
- Syringes
- Others
- Pens
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Retail Stores
- Others
Breakup by Disease Type:
- Type I Diabetes
- Type II Diabetes
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800